Hi A***h, I’m J***e, an HR recruiter at StrategyBrain partnering with M***l. I came across your profile and was impressed by your track record,founding I***s, leading strategy and corporate development at Q***m, and driving successful exits at E***n. Your expertise in M&A, due diligence, and strategic partnerships seems like an excellent fit. We’re currently looking for a Vice President of Corporate Development and Strategic Partnerships to help shape growth through mergers, acquisitions, and new alliances in the biotech and digital health space. Would you be open to a brief conversation to explore this opportunity? Looking forward to your thoughts. Best regards, J***e

Hi A***h, Great to hear you’re interested! A quick intro to the role and M***l before we lock in a time: • Company & Culture M***l is a mid-sized biotech and digital-health innovator with ~800 employees worldwide. We’re passionate about precision medicine and building scalable digital-health platforms. Our entrepreneurial culture emphasizes collaboration, fast decision-making and real impact on patient outcomes. • Role & Impact As VP, Corporate Development & Strategic Partnerships, you will: , Define and execute our M&A strategy,targeting acquisitions, strategic investments and joint ventures to accelerate growth , Lead full-cycle due diligence, valuation and negotiations in close partnership with finance, legal and R&D teams , Identify and manage partnerships across technology, healthcare and life-sciences to broaden our product portfolio and market reach , Advise the executive team on long-term business strategy, resource allocation and market priorities , Build and mentor a high-performing corporate-dev/partnerships team • Why It Fits Your Background Your experience founding and scaling I***s, driving M&A at Q***m, and building partnerships at E***n aligns perfectly with our needs. You’ll have autonomy to shape our growth roadmap and build a best-in-class deal team. • Growth & Support We offer competitive base + bonus + equity, comprehensive benefits, and a dedicated budget for professional development (conferences, coaching). You’ll work alongside a collaborative leadership team that values your strategic input. Would a brief call at 10:00 AM IST on Monday or 3:00 PM IST on Tuesday work for you? Let me know what suits you best, or if you’d like any additional details in advance. Looking forward to our conversation! Best regards, J***e HR Recruiter, StrategyBrain (partnered with M***l)

Hi A***h, Great,looking forward to our chat at 3:00 PM IST on Tuesday. I’ll send over a calendar invite shortly. To give you some context ahead of time: • Team Size Our corporate development group today is a tight, agile team of three full-time professionals (a Director of Transactions, an Associate, and an Analyst). As VP, you’d not only lead that team but also shape a planned expansion to five or six people over the next 12,18 months. • Strategic Priorities & M&A Pipeline 1. Bolt-on Acquisitions for Digital-Health Platforms , we’re actively evaluating 2,3 tuck-ins that can strengthen our remote-patient-monitoring and virtual-care offerings. 2. Precision-Medicine Capabilities , exploring one or two minority investments or partnerships in next-gen therapeutics data analytics. 3. Joint Ventures in AI-Driven Diagnostics , laying groundwork for a strategic alliance to accelerate product development in areas like oncology and rare disease. We’ll dive deeper into these priorities on our call, talk through timeline expectations and resource support, and answer any other questions you have. Let me know if there’s anything else you’d like me to prepare. Looking forward to speaking with you! Best, J***e HR Recruiter, StrategyBrain (on behalf of M***l)

Hi A***h , happy to dive into the details: 1. Digital-health tuck-ins • Target deal sizes: roughly USD 10,40 million per transaction, depending on revenue run-rate and technology fit. • Budget envelope: we’ve earmarked capital to complete 2,3 tuck-ins in the next 12 months, with flexibility to re-allocate across higher-impact targets. • Timeline to close: we’re planning 6,9 months from LOI to close, leveraging our small, nimble transaction team and external advisors for speed. 2. Team build-out • Current headcount: 3 (Director of Transactions, Associate, Analyst). • Growth plan: scale to 5,6 people over the next 12,18 months. First hires would include a Senior Manager (M&A integration), an additional Associate (target screening & diligence) and potentially a full-time financial modeler or strategic planning lead. • Skill mix: deep transaction execution chops, integration/project management experience, plus strong financial modeling and sector expertise in digital health/precision medicine. 3. Partnership with R&D on AI-driven diagnostics • You will sit on the JV steering committee alongside our Head of R&D and the diagnostics product team. • Expect weekly alignment calls to co-own technical diligence, roadmap prioritization, regulatory milestones and go-to-market planning. • This role is designed to be the bridge between corporate-dev strategy and R&D execution , you’ll help shape the joint-venture structure, equity split, and ongoing governance. Let me know if you’d like any further color before we chat on Tuesday at 3 PM IST. Looking forward to it! Best, J***e

Hi A***h, Happy to dig in: 1. ROI targets & tuck-in KPIs - IRR target of ~18,22% over a three-year hold period - Revenue synergies of 10,15% within 12 months (cross-sell into our existing digital-health base) - EBITDA accretion by month 18 - Customer retention ≥90% post-close - Key integration milestones (IT/data-platform convergence, regulatory alignment, go-to-market integration) met on a 3-, 6- and 12-month cadence Typical hurdles we’ve seen include: data/infrastructure compatibility, aligning QA/regulatory processes quickly, and retaining key target-company talent through the early transition. 2. AI-Diagnostics JV governance & decision rights - Steering Committee: four members (you and our Head of R&D + two from the JV partner), meeting bi-weekly to approve milestones and budgets - Board: six seats (three MediTech, three partner) - Voting thresholds: simple majority for routine budget allocations and hiring decisions; 75% (super-majority) for strategic pivots, capital raises >$5M, or equity adjustments - You’d lead agenda-setting, KPI tracking (e.g., algorithm validation milestones, regulatory filings, go-to-market pilots) and ensure clear handoffs between R&D and commercialization Let me know if you’d like more granularity on any of these points ahead of our Tuesday call. Look forward to discussing further! Best, J***e

Hi A***h, Thanks for the great questions,here’s a concrete example and our approach to a super-majority deadlock: 1. Past Digital-Health Tuck-In , Target: a $25M remote-patient-monitoring startup with complementary cloud analytics , Outcome: achieved a 20% IRR over three years (vs. our 18,22% goal) but realized only ~8% revenue synergy in year one (vs. 10,15%). , Integration levers we pulled: • Dedicated “integration sprint” team co-led by Product and Commercial,30-day milestones for platform APIs, regulatory alignment, and joint go-to-market bundles • Key‐talent retention incentives (graduated earn-outs tied to 12-month revenue targets) • Early cross-sell pilots in two flagship client accounts to prove bundle economics before full launch , Lesson learned: we under-indexed on data-pipeline compatibility, so in year two we doubled our engineering bandwidth and added a lightweight middleware layer,this recovered ~2% of the missed synergy by month 18. 2. Resolving a 75%-Threshold Deadlock in the JV , Pre-agreed escalation: if a strategic pivot (e.g., shifting R&D focus or raising >$5M) can’t clear 75% at the Steering Committee, we trigger a “resolution workshop” with the Executive Sponsors (CEOs of each party). , Mediation mechanics: • Each sponsor brings forward a one-page proposal outlining risk/ROI, time to value, and fallback options • A neutral, senior advisor (e.g., an external board member) chairs the session to guide toward a compromise,often blending elements from both sides or agreeing on a staged pilot with pre-defined kill-criteria , If consensus still eludes us, a sunset vote kicks in: we either accept the status quo for six more months or put that pivot on hold and re-allocate capital to agreed alternate priorities. I hope this gives you a clear sense of how we measure success, course-correct on integration, and handle super-majority votes. Let me know if you’d like to drill into any angle before our Tuesday call at 3:00 PM IST. Best, J***e

Hi A***h,great questions. Here’s how we approached both scenarios: 1. Middleware fix scoping, funding & sprint alignment • Scoping: we kicked off a 4-week technical discovery with our platform architects and the target’s dev leads to map data flows, estimate effort and define a lean middleware spec. • Funding: we tapped our negotiated integration reserve (typically 3,5% of deal value) and got quick CFO approval for a focused, short-term budget. • Sprint alignment: we staffed a two-engineer squad plus a data-architecture lead and an integration PM; managed work via a shared Jira backlog; ran 2-week sprints with daily scrum-of-scrums and bi-weekly demos to surface blockers and validate incremental deliverables. 2. Resolution-workshop fallback & kill criteria • Real-world fallback: in one diagnostics JV, partners deadlocked on a broad R&D pivot. We agreed to run a narrow POC on a single algorithm module instead of the full expansion. • Kill criteria: defined up front in our JV charter as a 12-week gate with two metrics,≥85% assay accuracy and completion of a regulatory feasibility memo. If either threshold wasn’t met by the deadline, we would sunset that POC and re-deploy resources to agreed alternate initiatives. Happy to dive deeper on Tuesday at 3:00 PM IST and explore how you’d apply similar levers in our tuck-ins and JVs. Let me know if there’s anything else you’d like me to prepare. Best, J***e